Case Report: Favorable Response to the Tyrosine Kinase Inhibitor Apatinib in Recurrent Merkel Cell Carcinoma
Open Access
- 3 March 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Abstract
Background: As angiogenesis is an essential step in tumor growth and metastasis, the tyrosine kinase inhibitor (TKI) apatinib has become a revolutionary anticancer therapy across various malignancies. However, its efficiency and safety in Merkel cell carcinoma (MCC) are uncertain.Case presentation: The current study described the case of a 91-year-old man who presented with a 3.2 × 3.0 × 2.2 cm rapidly growing, solitary tumor of the right lower eyelid. It was diagnosed as MCC pathologically. Twenty-seven days after the surgery, the patient returned to the hospital with recurrent MCC. Apatinib was then administered to this patient. The patient had a complete response (CR) to apatinib after 4.4 months of targeted therapy. Twenty-seven months of progression-free survival (PFS) was achieved with controllable treatment-related adverse events (AEs).Conclusion: Treatment with apatinib demonstrated clinical benefit in our patient with recurrent MCC, highlighting its potential utility in other MCC patients. Further clinical trials are needed to determine the efficacy and safety of apatinib in MCC patients.Keywords
Funding Information
- National Natural Science Foundation of China (81570884, 81770961)
This publication has 21 references indexed in Scilit:
- Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network, 2018
- Merkel cell carcinoma: Current US incidence and projected increases based on changing demographicsJournal of the American Academy of Dermatology, 2018
- Merkel cell carcinomaNature Reviews Disease Primers, 2017
- Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needsEuropean Journal of Cancer, 2017
- Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinomaCancer Medicine, 2016
- Apatinib for molecular targeted therapy in tumorDrug Design, Development and Therapy, 2015
- Merkel Cell Carcinoma: 30-Year Experience from a Single InstitutionAnnals of Surgical Oncology, 2012
- Merkel Cell Carcinoma: 27-Year Experience at the Peter MacCallum Cancer CentreInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: Analysis of 5823 cases as the basis of the first consensus staging systemJournal of the American Academy of Dermatology, 2010
- Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU featuresJournal of the American Academy of Dermatology, 2008